Implantable Insulin Pump in Type II Diabetes

Michael Bergman, Stephen Olczak, Patricia B. Carroll, William M. Rupp, Jose J. Barbosa, Perry J. Blackshear, Hildy B. Mccarthy, Thomas D. Rohde, Fay J. Goldenberg, Thomas G. Rublein, Frank B. Dorman, Henry Buchwald

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: In their article on the use of an implantable pump (July 29 issue),1 Rupp et al. demonstrated that normal triglyceride values could be further reduced by means of intravenous insulin infusion in nonobese patients with Type II diabetes. Several groups of workers2 3 4 have already reported that subcutaneous insulin infusion restores triglyceride concentrations to normal in Type I diabetics. The presumed mechanism for this reduction is the stimulation of lipoprotein lipase activity, which is deficient during insulin deprivation, resulting in the enhanced clearance of triglyceride-rich particles.5 The hypertriglyceridemia commonly observed in obese Type II diabetics is related to. . .

Original languageEnglish (US)
Pages (from-to)1579-1580
Number of pages2
JournalNew England Journal of Medicine
Issue number25
StatePublished - Dec 16 1982


Dive into the research topics of 'Implantable Insulin Pump in Type II Diabetes'. Together they form a unique fingerprint.

Cite this